-
Jan 17, 2025 | 
mondaq.com | Anna K. Abram |Nathan Brown
On January 7, the FDA made available draft guidance on the development of drugs andbiological products for weight reduction within the Center for DrugEvaluation and Research intended for reduction and long-termmaintenance of body weight in patients with obesity or who areoverweight.
-
Jan 14, 2025 | 
jdsupra.com | Anna K. Abram |Nathan Brown
January 14, 2025
To embed, copy and paste the code into your website or blog:
On January 7, the FDA made available draft guidance on the development of drugs and biological products for weight reduction within the Center for Drug Evaluation and Research intended for reduction and long-term maintenance of body weight in patients with obesity or who are overweight.
-
Jan 14, 2025 | 
akingump.com | Anna K. Abram |Nathan Brown
By: Anna K. Abram, Nathan A. BrownOn January 7, the FDA made available draft guidance on the development of drugs and biological products for weight reduction within the Center for Drug Evaluation and Research intended for reduction and long-term maintenance of body weight in patients with obesity or who are overweight.
-
Jan 6, 2025 | 
jdsupra.com | Anna K. Abram |Kevin Brady |Sean Feely
January 6, 2025 Anna Abram, Shawn Maree Bishop, Kevin Brady, Sean Feely, Kandis McClure, Samuel Olswanger, Jocelyn Wiles Akin Gump Strauss Hauer & Feld LLP + Follow x Following x Following - Unfollow Contact To embed, copy and paste the code into your website or blog: As the new year begins, change is afoot inside the Beltway as the 119th Congress gets underway and Washington prepares for President Trump’s second administration. While change is bringing uncertainty on some fronts, health care...
-
Dec 10, 2024 | 
mondaq.com | Cheese Consumers |Anna K. Abram |Nathan Brown |Caroline D. Kessler
On December 5, 2024, FDA unveiled the draft guidance for industry regarding
accelerated approval for drugs and biologics. This guidance
provides additional information regarding the development of drugs
and biologics to treat serious conditions for which there is an
unmet need, and for which the sponsor is seeking accelerated
approval.
-
Dec 6, 2024 | 
akingump.com | Anna K. Abram |Nathan Brown |Caroline D. Kessler
By: Anna K. Abram, Nathan A. Brown, Caroline D. KesslerOn December 5, 2024, FDA unveiled the draft guidance for industry regarding accelerated approval for drugs and biologics. This guidance provides additional information regarding the development of drugs and biologics to treat serious conditions for which there is an unmet need, and for which the sponsor is seeking accelerated approval.
-
Dec 2, 2024 | 
jdsupra.com | Anna K. Abram |Nathan Brown
In recent days, President-elect Trump has made progress in announcing the names of various individuals he intends to nominate to serve in some of the most senior and influential leadership positions at the Department of Health and Human Services (HHS) and which also require Senate confirmation. The first of these announcements was that President-elect Trump intends to nominate RFK Jr. to serve as HHS Secretary.
-
Nov 27, 2024 | 
mondaq.com | Anna K. Abram |Marlee Gallant
AdvaMed, the world's largest medical technology association
representing device, diagnostics and digital technology companies,
released a white paper that reviews the current landscape
of artificial intelligence (AI)-based applications and products in
the health care sector, and identifies steps to accelerate the use
of AI in medical technologies.
-
Nov 26, 2024 | 
mondaq.com | Anna K. Abram |Nathan Brown
In recent days, President-elect Trump has made progress in
announcing the names of various individuals he intends to nominate
to serve in some of the most senior and influential leadership
positions at the Department of Health and Human Services (HHS) and
which also require Senate confirmation. The first of these
announcements was that President-elect Trump intends to nominate
RFK Jr. to serve as HHS Secretary.
-
Nov 25, 2024 | 
akingump.com | Anna K. Abram |Marlee Gallant
By: Anna K. Abram, Marlee P. GallantAdvaMed, the world’s largest medical technology association representing device, diagnostics and digital technology companies, released a white paper that reviews the current landscape of artificial intelligence (AI)-based applications and products in the health care sector, and identifies steps to accelerate the use of AI in medical technologies.
